Ca-125, A Biomarker in Acute-Decompensated Heart Failure. Preliminary Study.

Open access

Abstract

Background. CA-125 is a tumor antigen expressed on the surface of ovarian cells, used to monitor the treatment of ovarian cancer (normal upper limit is 35U/mL), but it seems also to have a role as biomarker in heart failure (HF).

Aim. To determine CA-125 changes in acute-decompensated HF (ADHF) patients.

Method. The study group included 110 patients (mean age 72±10 years, 63% men) with ADHF caused by ischemic cardiomyopathy. The subjects were clinically, ecocardiographically and biologically (NT-proBNP, PCR, serum uric acid (sUA), CA-125) evaluated.

Results. CA-125 at admission was 53±33 U/mL and decreased at discharge to 34±17 U/mL, without any difference between males and females. The mean level of CA-125 was significantly higher in patients with pleural effusion.

There was a significant difference between NT-proBNP at admission in obese versus normoponderal patients, which was maintained at discharge. In the same time, the CA-125 did not show significant differences between obese and normoponderal subjects at admission and discharge. The mean level of CA-125 was significantly higher for subjects with reduced ejection fraction and with elevated left ventricular filling pressures versus subjects with preserved ejection fraction and normal left ventricular filling pressures.

The CA-125 correlated with LVEF (R=-0.221, p=0.02), with NT-proBNP (R=0.371, p<0.001), with the inflammation marker - PCR (R=0.284, p=0.003) and oxidative stress marker - sUA (R=0.234, p=0.015).

Conclusions. The wide availability of CA-125, its relatively low cost, its correlation with known prognostic markers in HF and the additional information provided make it a valuable biomarker that can be used in monitoring ADHF patients.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. McMurray JJ V Adamopoulos S Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart. Rev Port Cardiol. 2013;32(7-8):e1--641--e61.doi:10.1093/eurheartj/ehs104.

  • 2. Ma J Zhao YWang Y Guo Y Li J. Tumor marker levels in patients aged 85 years and older with chronic heart failure. Eur J Intern Med. 2013;24(5):440-443. doi:10.1016/j.ejim.2013.04.002.

  • 3. Miñana G Palau P Núñez J Sanchis J. The Tumor Marker CA125 and Heart Failure. Eur Heart J. 2010;31(14):1752-1763. doi:10.1093/eurheartj/ehq142.

  • 4. Turgut O Tandogan I Yilmaz MB Gul I Zorlu A. CA125 in heart failure: Implications for immunoinflammatory activity. Int J Cardiol. 2011;146(1):99-100. doi:10.1016/j.ijcard.2010.05.077.

  • 5. Huang F Zhang K Chen J et al. Elevation of carbohydrate antigen 125 in chronic heart failure may be caused by mechanical extension of mesothelial cells from serous cavity effusion. Clin Biochem. 2013;46(16-17):1694-1700. doi:10.1016/j.clinbiochem.2013.09.008.

  • 6. Monteiro S Franco F Costa S et al. Prognostic value of CA125 in advanced heart failure patients. Int J Cardiol. 2010;140(1):115-118. doi:10.1016/j.ijcard.2008.11.023.

  • 7. Turgut O Tandogan I Yilmaz MB Gul I Gurlek A. CA125 levels among patients with advanced heart failure: An emerging independent predictor for survival. Int J Cardiol. 2010;145(1):71. doi:10.1016/j.ijcard.2009.04.030.

  • 8. Zorlu A Tandogan I Yilmaz MB. CA-125 an omitted part of the heart. Hear Lung Circ. 2011;20(5):345. doi:10.1016/j.hlc.2011.01.025.

  • 9. D’Aloia A Faggiano P Aurigemma G et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: Relation to clinical severity hemodynamic and doppler echocardiographic abnormalities and short-term prognosis. J Am Coll Cardiol. 2003;41(10):1805-1811. doi:10.1016/S0735-1097(03)00311-5.

  • 10. Núñez J Miñana G González M et al. Antigen carbohydrate 125 in heart failure: Not just a surrogate for serosal effusions? Int J Cardiol. 2011;146(3):473-474. doi:10.1016/j.ijcard.2010.12.027.

  • 11. Nunez J Llacer P Nunez E et al. Antigen carbohydrate 125 and creatinine on admission for prediction of renal function response following loop diuretic administration in acute heart failure. Int J Cardiol. 2014;174(3):516-523. doi:10.1016/j.ijcard.2014.04.113.

  • 12. Núñez J Núñez E Sanchis J et al. Antigen carbohydrate 125 and brain natriuretic peptide serial measurements for risk stratification following an episode of acute heart failure. Int J Cardiol. 2012;159(1):21-28. doi:10.1016/j.ijcard.2011.02.001.

  • 13. Vizzardi E D’Aloia A Pezzali N Bugatti S Curnis A Dei Cas L. Long-term prognostic value of CA 125 serum levels in mild to moderate heart failure patients. J Card Fail. 2012;18(1):68-73. doi:10.1016/j.cardfail.2011.09.012.

  • 14. Miñana G Palau P Núñez J Sanchis J. The Tumor Marker CA125 and Heart Failure. Rev Española Cardiol (English Ed. 2010;63(10):1213-1214. doi: 10.1016/S1885-5857(10)70240-1.

  • 15. Yilmaz MB Nikolaou M Solal AC. Tumour biomarkers in heart failure: Is there a role for CA-125? Eur J Heart Fail. 2011;13(6):579-583. doi:10.1093/eurjhf/hfr022.

  • 16. Topatan B Basaran A. CA-125 and heart failure: Deja vu or “still to be seen.” Int J Cardiol. 2010;145(3):626-629. doi:10.1016/j.ijcard.2010.09.060.

  • 17. Huang F Chen J Liu Y Zhang K Wang J Huang H. New mechanism of elevated CA125 in heart failure: The mechanical stress and inflammatory stimuli initiate CA125 synthesis. Med Hypotheses. 2012;79(3):381-383. doi:10.1016/j.mehy.2012.05.042.

  • 18. Napan S Aussawapokee T Nargileci E Qureshi A Khadra S Stroger JH. Prognostic Significance of Carbohydrate Antigen 125 in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2010;55(10):A30.E292. doi:10.1016/S0735-1097(10)60293-8.

  • 19. Nunez J Minana G Nunez E Sanchis J. Antigen carbohydrate 125 in heart failure: A promising clinical tool. Int J Cardiol. 2011;150(3):369-370. doi:10.1016/j.ijcard.2011.05.089.

  • 20. Sánchez-Marteles M Rubio Gracia J Giménez López I. Pathophysiology of acute heart failure: a world to know. Rev Clin Esp. 2015;216(1):38-46. doi:10.1016/j.rce.2015.09.010.

  • 21. Nunez J Merlos P Facila L et al. Prognostic effect of carbohydrate antigen 125-guided therapy in patients recently discharged for acute heart failure (CHANCEHF). Study design. [Spanish]. Rev Esp Cardiol. 2015;68(2):121-128. doi:http://dx.doi.org/10.1016/j.recesp.2014.03.018.

Search
Journal information
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 242 156 4
PDF Downloads 142 84 4